#TYME STOCK PRICE PROFESSIONAL#
Trading on margin increases the financial risks.īefore deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.įusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. operates as a subsidiary of Syros Pharmaceuticals, Inc. As of September 16, 2022, Tyme Technologies, Inc. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.
The company was formerly known as Global Group Enterprises Corp. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors.
#TYME STOCK PRICE TRIAL#
Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.
0 kommentar(er)
